BIO-TECHNE Corp Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
BIO-TECHNE Corp (TECH) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum of 4.10% for the 12-month period ending 2026-06-30, per its 10-K filed 2026-08-24.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum · last filed 2026-08-24
- BIO-TECHNE Corp share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2012-03-31 was 1.20%.
- BIO-TECHNE Corp share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2026 was 4.10%, a 6.82% decline from fiscal 2025.
- BIO-TECHNE Corp share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2025 was 4.40%, a 8.33% decline from fiscal 2024.
- BIO-TECHNE Corp share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2024 was 4.80%, a 9.09% increase from fiscal 2023.
- BIO-TECHNE Corp share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2023 was 4.40%, a 69.23% increase from fiscal 2022.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 12 month |
|---|---|---|---|---|
| 2026-06-30 | 4.10% 10-K · filed 2026-08-24 | |||
| 2025-06-30 | 4.40% 10-K · filed 2026-08-24 | |||
| 2024-06-30 | 4.80% 10-K · filed 2026-08-24 | |||
| 2023-06-30 | 4.40% 10-K · filed 2025-08-22 | |||
| 2022-06-30 | 2.60% 10-K · filed 2024-08-22 | |||
| 2021-06-30 | 0.70% 10-K · filed 2023-08-23 | |||
| 2020-06-30 | 1.90% 10-K · filed 2022-08-24 | |||
| 2014-06-30 | 2.10% 10-K · filed 2014-08-29 | |||
| 2013-06-30 | 1.40% 10-K · filed 2014-08-29 | |||
| 2012-06-30 | 2.00% 10-K · filed 2014-08-29 | |||
| 2012-03-31 | 1.20% 10-Q · filed 2012-05-10 | 2.00% 10-Q · filed 2012-05-10 | ||
| 2011-12-31 | 1.90% 10-Q · filed 2012-02-07 | |||
| 2011-06-30 | 2.30% 10-K · filed 2013-08-29 | |||
| 2011-03-31 | 2.00% 10-Q · filed 2012-05-10 | |||
| 2010-12-31 | 2.00% 10-Q · filed 2012-02-07 | |||
| 2010-06-30 | 3.10% 10-K · filed 2012-08-29 | |||
| 2009-06-30 | 3.50% 10-K · filed 2011-08-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |